Notice of Results and Investor Webinar

Accrol Group Holdings PLC
26 January 2024
 

 

26 January 2024

Accrol Group Holdings plc

("Accrol, or the "Group")

 

Notice of Half Year Results and Investor Webinar

 

Accrol (AIM: ACRL), the UK's leading independent tissue converter, will release its Half Year Results for the six months to 31 October 2023 on Tuesday 30 January 2024.

 

As part of the Group's Results roadshow, the management will host an online investor presentation and Q&A session. This will take place on Friday, 2 February 2024 at 1.30pm. Anyone wishing to participate should register for the event with PI World at: https://bit.ly/ACRL_H124_results_webinar.

 

 

For further information, please contact:

 

 


Accrol Group Holdings plc


Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer


Chris Welsh, Chief Financial Officer


 


Zeus (Nominated Adviser & Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King

Tel: +44 (0) 203 829 5000



Shore Capital Stockbrokers (Joint Broker)

Tel: +44 (0) 20 7408 4090

Malachy McEntyre/ Mark Percy / James Thomas / Isobel Jones




Belvedere Communications Limited


Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525


accrolpr@belvederepr.com

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK.

 

For more information, please visit www.accrol.co.uk.

 

Link for Accrol Today video: https://www.accrol.co.uk/our-business/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings